The overarching goal of the Tissue and Pathology Core (TPC) is to facilitate translational research involving the acquisition or use of biological samples within the SPORE. To accomplish this goal, the Core will offer a range of services for SPORE investigators. These include: 1) Providing a tissue and blood repository;2) Collecting, storing, processing, and analyzing tissue and blood from participants on SPORE clinical trials;and 3) Providing a variety of readily accessible pathology and technical services, integrated with clinical information. In addition to standard pathology techniques, the TPC will offer several state-of-the- art technologies including circulating tumor cell capture and analysis. Lastly, the TPC will centralize and prioritize access of biological samples to investigators collected in the SPORE. A key strength of the TPC is the ability to bank frozen tumor tissue. The Core has a pre-existing collection of over 2,600 frozen breast cancer specimens acquired during the previous SPORE and this resource will continue to be expanded. The Core also will maintain a blood sample repository that will build upon the current collection of samples from 10,000 patients with breast cancer and from 2,400 individuals at high risk of developing breast cancer. In order to optimize the utility of the specimen collections for translational research, the samples in the repository are linked to clinical data through caTissue. The TPC will work closely with the Clinical Trials Core to procure research biopsies and other tissues from participants on SPORE clinical trials. The TPC will use caTissue to catalogue these specimens as well. Importantly, the Core will be directly involved in the analysis of these specimens, and will interact extensively with the four projects. To ensure that project-related tissue based research is seamless;a specific team pathologist from the TPC has been identified as a collaborator for each project. In addition to working with SPORE investigators, the Core will work with investigators throughout the DF/HCC, with other Breast Cancer SPORE programs, and with researchers at centers around the world. The TPC facilitates clinical research involving the acquisition or use of biological samples within the SPORE. Three of the four projects have proposed clinical trials that include research biopsies (Projects 2, 3, 4). The TPC will oversee the collection, storage, quality assessment, and processing of these biopsies. During the course of the SPORE, we anticipate supporting other investigators who will conduct tissue-intensive trials either as part of the projects or through a career development program award or developmental project.

Public Health Relevance

The Tissue and Pathology Core facilitates translational research involving the acquisition or use of biological samples. The collection of tissue and blood from healthy and diseased women is vital to translational research. Having the TPC resource will advance our ability to prevent, diagnose and treat breast cancer. The Core will enable the SPORE toward translational discoveries in the near-term, and a new wave of scientific challenges.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA168504-02
Application #
8753994
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
2
Fiscal Year
2014
Total Cost
$188,731
Indirect Cost
$24,053
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Willis, Nicholas A; Panday, Arvind; Duffey, Erin E et al. (2018) Rad51 recruitment and exclusion of non-homologous end joining during homologous recombination at a Tus/Ter mammalian replication fork barrier. PLoS Genet 14:e1007486
Kabraji, Sheheryar; Ni, Jing; Lin, Nancy U et al. (2018) Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? Clin Cancer Res 24:1795-1804
Bian, X; Gao, J; Luo, F et al. (2018) PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene 37:341-351
Bertrand, Kimberly A; Eliassen, A Heather; Hankinson, Susan E et al. (2018) Circulating Hormones and Mammographic Density in Premenopausal Women. Horm Cancer 9:117-127
Kensler, Kevin H; Beca, Francisco; Baker, Gabrielle M et al. (2018) Androgen receptor expression in normal breast tissue and subsequent breast cancer risk. NPJ Breast Cancer 4:33
Li, Ben B; Qian, Changli; Roberts, Thomas M et al. (2018) Targeted Profiling of RNA Translation. Curr Protoc Mol Biol :e71
Li, Ben B; Qian, Changli; Gameiro, Paulo A et al. (2018) Targeted profiling of RNA translation reveals mTOR-4EBP1/2-independent translation regulation of mRNAs encoding ribosomal proteins. Proc Natl Acad Sci U S A 115:E9325-E9332
Guerriero, Jennifer L (2018) Macrophages: The Road Less Traveled, Changing Anticancer Therapy. Trends Mol Med 24:472-489
Kuang, Yanan; Siddiqui, Bilal; Hu, Jiani et al. (2018) Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. NPJ Breast Cancer 4:22
Liu, Hui; Murphy, Charles J; Karreth, Florian A et al. (2018) Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. Cancer Discov 8:354-369

Showing the most recent 10 out of 66 publications